Q3 2020 Sales Performance
Blenrep: first-in-class treatment for multiple myeloma
gsk
Positive response, encouraging demand
■ REMS fully operationalised; >500 HCPs enrolled
200+ patients enrolled in REMS (end Q3)
■ Share of voice1 amongst top 3 MM² treatments
■Included in NCCN Guidelines
NOC0113-0016-01
Development in earlier lines continues
■ Studying optimal dosing volume and scheduling
■ Investigating synergistic combinations:
■ DREAMM-5 platform study; preliminary data on GSI
combination expected 2021
■ DREAMM-4 combination with pembrolizumab; data
in-house, presentation expected 1H21
Upcoming read-outs
R Galy
BLENREP
(belantamab mafodotin-blmf)
for injection
100 mg/vial
CAUTION: Hazardous Agent
For intravenous infusion
after reconstitution and
diation
Single-dose val
Decard unused portion
No preservative.
No US standard al potency.
Dispense the enclosed
Madication Guide to gach
patient
BLENREP
1. Brand Impact Report; Sept 2020
2. Multiple Myeloma
Highly-skilled and
experienced salesforce
In-person access to HCPs
highest amongst MM
competitive set¹
2021
Prelim data on
GSI combo
(DREAMM-5)
Ph3 data in 2L
pom/dex combo
(DREAMM-8)
Ph3 data in 2L
bor/dex combo
(DREAMM-7)
2022
2023
POC data 3L+
pembro combo
(DREAMM-4)
Dose selection data in
1L combo
(DREAMM-9)
Ph3 data in 3L+
mono for failed len+PI
(DREAMM-3)
2024
35View entire presentation